ASH 2021: Novel BCMA-Targeting Bispecific Antibody Under Study in Resistant Myeloma
Posted: Thursday, December 23, 2021
According to findings presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 900), TNB-383B, a B-cell maturation antigen (BCMA)-targeting bispecific antibody, is well tolerated among patients with relapsed and refractory multiple myeloma, with an objective response rate of 79% in the dose-escalation cohort of a phase I trial. Shaji K. Kumar, MD, of the Mayo Clinic, Rochester, Minnesota, and colleagues noted that enrollment into the dose-expansion arm is ongoing.
In this early-phase study, the authors reported on 118 evaluable patients with relapsed or refractory multiple myeloma who received TNB-383B. Approximately 75 patients received at least 40 mg in the dose-escalation plus dose-expansion phase.
The authors reported that treatment-related adverse events occurred in 54 patients (46%), with 37 of these patients having received at least 40 mg. Adverse events related to infection occurred in 38 patients (32%), with 23 patients having received at least 40 mg. The most common treatment-related adverse events were cytokine-release syndrome (52 patients), neutropenia (24 patients), and anemia (21 patients).
After a median follow-up of 8 months, for patients who received at least 40 mg of TNB-383B every 3 weeks, the objective response rate was 81%, with a very good partial response or better rate of 69%. At the same dosage in the combined dose-escalation and -expansion cohorts (60 patients), the authors observed an objective response rate of 60%, with a median follow-up of 4.3 months. These patients reported a very good partial response rate of 40%.
Disclosure: For full disclosures of the study authors, visit ash.com.